抗纤维化治疗启动后肺纤维化患者肺功能轨迹:荷兰国家注册研究
该研究基于荷兰16家医院的国家多中心注册数据,纳入538例(PPF 142例,IPF 396例)接受抗纤维化治疗且治疗前后均有至少两次肺功能检查的患者,采用线性混合效应模型分析治疗前后1年的FVC变化轨迹。结果显示两组FVC下降均显著减缓,PPF组年化FVC下降由治疗前412 mL降至治疗后18 mL,IPF组由158 mL降至38 mL,但治疗后第一年仍有23.9%的PPF和28.0%的IPF患者出现疾病进展。
要点
- PPF患者抗纤维化治疗前年化FVC下降412 mL,治疗后第一年降至18 mL。
- IPF患者年化FVC下降由治疗前158 mL降至治疗后38 mL。
- 治疗后第一年PPF和IPF分别有23.9%和28.0%患者仍出现疾病进展。
核心结论
- PPF和IPF患者启动抗纤维化治疗后FVC下降均显著减缓,但仍有相当比例患者出现疾病进展。
研究设计与样本
- 荷兰全国16家医院的多中心注册研究,纳入538例接受抗纤维化治疗且治疗前后均有至少两次肺功能检查的患者(PPF 142例,IPF 396例)。
- 采用线性混合效应模型分析抗纤维化治疗启动前后各1年的肺功能轨迹。
主要发现
- PPF组治疗前年化FVC下降412 mL(95%CI 308-517 mL),治疗后第一年下降18 mL(95%CI 9-124 mL)。
- IPF组治疗前年化FVC下降158 mL(95%CI 78-239 mL),治疗后第一年下降38 mL(95%CI 24-101 mL)。
- 两组治疗后FVC下降均显著减缓,PPF组变化幅度更大(p=0.0006)。
- 治疗后第一年,PPF组23.9%、IPF组28.0%的患者出现疾病进展。
临床怎么用
- 真实世界数据支持抗纤维化治疗可减缓PPF和IPF患者的FVC下降。
- 治疗后仍需监测疾病进展,早期识别进展患者以便调整治疗或纳入临床试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Real-world data on lung function course of patients with progressive pulmonary fibrosis (PPF) treated with anti-fibrotic medication are limited. We evaluated forced vital capacity (FVC) decline in patients with PPF and idiopathic pulmonary fibrosis (IPF) who started anti-fibrotic treatment. METHODS: This was a nationwide multi-centre registry study in 16 hospitals throughout the Netherlands. Patients treated with anti-fibrotic medication, with at least two in-hospital pulmonary function tests before and after the initiation of anti-fibrotic treatment, were included. Linear mixed-effects modelling was used to analyse lung function trajectories 1 year before and after the start of anti-fibrotic treatment. RESULTS: Data from 538 patients (n = 142 with PPF, n = 396 with IPF) were analysed. In PPF, the mean annualised FVC decline was 412 mL (95% confidence interval [CI]: 308-517 mL) before the initiation of anti-fibrotic treatment, and 18 mL (95% CI: 9-124 mL) in the first year after. The corresponding declines for IPF were 158 mL (95% CI: 78-239 mL) and 38 mL (95% CI: 24-101 mL). In both groups, treatment significantly slowed down FVC decline, although the change was larger in the PPF group (p = 0.0006). In the first year after treatment initiation, 23.9% of patients with PPF and 28.0% with IPF had disease progression. CONCLUSION: The FVC decline significantly slowed after the initiation of treatment for both IPF and PPF. Nevertheless, a significant proportion of patients exhibited disease progression, despite the start of anti-fibrotic treatment. Early identification of these patients is crucial for treatment adaptations and inclusion in clinical trials.
引用
- Platenburg MGJP, Nakshbandi G, Moor CC, et al. Lung Function Course of Patients With Pulmonary Fibrosis After Initiation of Anti-Fibrotic Treatment: Real-World Data From the Dutch National Registry. Respirology. 2025. PMID: 40122143. doi:10.1111/resp.70030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。